Showing 1881-1890 of 2150 results for "".
- Heine Announces Launch of Omega 600 Lightweight Indirect Ophthalmoscopehttps://modernod.com/news/heine-announces-launch-of-new-omega-600-lightweight-indirect-ophthalmoscope/2478842/Heine has launched its newest indirect ophthalmoscope, the Omega 600. The Omega 600 includes a new design that makes it the lightest high-end indirect on the market courtesy of a new ultralight battery, according to Heine. Other new features are Heine’s visionBOOST technology, which is des
- Gemini Therapeutics Debuts as Publicly Traded Company Focused on Age-Related Macular Degenerationhttps://modernod.com/news/gemini-therapeutics-debuts-as-publicly-traded-company-focused-on-age-related-macular-degeneration/2478841/Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, the resulting combined company, will commence trading its shares today on the Nasdaq Global Market u
- EU Authorizes AstraZeneca’s COVID-19 Vaccine Amid Supply Disputehttps://modernod.com/news/eu-authorizes-astrazenecas-covid-19-vaccine-amid-supply-dispute/2478816/The European Commission on Friday granted a conditional marketing authorization to AstraZeneca and the University of Oxford’s AZD1222 for people aged 18 years and older, making it the third COVID-19 vaccine authorized in the EU, following Pfizer and BioNTech’s vaccine Comirnaty, as we
- James Reid Named CEO of Versant Healthhttps://modernod.com/news/james-reid-named-ceo-of-versant-health/2478762/MetLife announced that James Reid has been named CEO of Versant Health, a managed vision care company and wholly owned subsidiary of MetLife. The appointment is effective April 1. “James brings extensive and varied experience in the Group Benefits market to Versant Health,” Todd Katz, chai
- NTC Grants to Zhaoke Exclusive License and Distribution Rights in Asia for NTC014 for Bacterial Conjunctivitishttps://modernod.com/news/ntc-grants-to-zhaoke-exclusive-license-and-distribution-rights-in-asia-for-ntc014-for-bacterial-conjunctivitis/2478758/Italy-based NTC and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited announced an agreement for exclusive license and distribution rights of NTC014 fixed combination of a quinolone antibiotic and a NSAID in eye drops. Zhaoke will market NTC014 in
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Treatment Roclandahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-treatment-roclanda/2478740/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension for whom monoth
- Moderna’s COVID-19 Vaccine Becomes Second to Nab EU Authorizationhttps://modernod.com/news/modernas-covid-19-vaccine-becomes-second-to-nab-eu-authorization/2478725/The European Commission on Wednesday granted a conditional marketing authorization for Moderna’s COVID‑19 vaccine mRNA-1273, making it the second coronavirus vaccine authorized in the EU. The decision comes hours after the European Medicines Agency (EMA) had recommended authorizing mRNA-127
- VisionQuest Biomedical Gains FDA 510(k) Clearance for the Image Quality Analyzer Softwarehttps://modernod.com/news/visionquest-biomedical-gains-fda-510k-clearance-for-the-image-quality-analyzer-software/2478706/VisionQuest Biomedical announced that the company has received 510(k) clearance from the FDA to market the Image Quality Analyzer (IQA) software, which reduces unreadable images captured in teleretinal screening programs by retinal photographers. The IQA is a software system intended for u
- Nicox’s Licensee Bausch + Lomb Secures Approval of Vyzulta in Colombiahttps://modernod.com/news/nicoxs-licensee-bausch-lomb-secures-approval-of-vyzulta-in-colombia/2478694/Nicox announced that its partner, Bausch + Lomb, has received approval for latanoprostene bunod ophthalmic solution, 0.024% (marketed as Vyzulta In the United States) in Colombia, where it will be marketed under the brand name Cliropta. Vyzulta is currently commercialized in the United Sta
- Norlase Announce the Addition of Distributor Partnershipshttps://modernod.com/news/norlase-announce-the-addition-of-distributor-partnerships/2478690/Norlase announced the addition of distributor partnerships in Eastern Europe, Middle East, Oceania and Southeast Asia. “Following our recent expansion into the broader European countries, we are thrilled to establish distributor relationships in these key markets,” Oliver Hvidt, CEO and Pr